Aequus Pharmaceuticals Inc.
AQS.V
TSX
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 44.50% | 27.28% | 27.34% | 18.81% | 4.16% |
| Total Depreciation and Amortization | -28.64% | -5.93% | -5.66% | -5.04% | -1.97% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 359.34% | 327.66% | -37.27% | -85.78% | -82.87% |
| Change in Net Operating Assets | 465.58% | 356.69% | -25.62% | -105.48% | -132.40% |
| Cash from Operations | 84.18% | 57.29% | 28.44% | -33.52% | -58.57% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | -83.98% | -64.77% | -30.00% | 86.66% | 392.57% |
| Total Debt Repaid | 48.12% | -6.30% | -7.97% | 10.01% | 11.37% |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -86.15% | -69.23% | -33.17% | 99.02% | 565.78% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | 198.58% | -- | -- | -- |
| Net Change in Cash | -163.21% | -209.91% | -52.05% | 86.68% | 101.08% |